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Abstract
Background: Patients with chronic obstructive pulmonary disease (COPD) often experience exacerbations of the
disease that require hospitalization. Current guidelines offer little guidance for identifying patients whose clinical
situation is appropriate for admission to the hospital, and properly developed and validated severity scores for
COPD exacerbations are lacking. To address these important gaps in clinical care, we created the IRYSS-COPD
Appropriateness Study.
Methods/Design: The RAND/UCLA Appropriateness Methodology was used to identify appropriate and
inappropriate scenarios for hospital admission for patients experiencing COPD exacerbations. These scenarios were
then applied to a prospective cohort of patients attending the emergency departments (ED) of 16 participating
hospitals. Information was recorded during the time the patient was evaluated in the ED, at the time a decision
was made to admit the patient to the hospital or discharge home, and during follow-up after admission or
discharge home. While complete data were generally available at the time of ED admission, data were often
missing at the time of decision making. Predefined assumptions were used to impute much of the missing data.
Discussion: The IRYSS-COPD Appropriateness Study will validate the appropriateness criteria developed by the
RAND/UCLA Appropriateness Methodology and thus better delineate the requirements for admission or discharge
of patients experiencing exacerbations of COPD. The study will also provide a better understanding of the
determinants of outcomes of COPD exacerbations, and evaluate the equity and variability in access and outcomes
in these patients.
Background
Chronic obstructive pulmonary disease (COPD) is one
of the most common chronic diseases, and its preva-
lence is expected to increase over the next few decades
[1-3]. COPD is a leading cause of death in developed
countries, and patients with COPD generally have a sub-
stantial deterioration in their quality of life [4,5].
Patients often experience exacerbations of COPD, and
these often require hospitalization.
Various guidelines have been developed to provide
clinicians with recommendations for managing patients
with stable COPD as well as those experiencing exacer-
bations of the disease [6-8]. However, these guidelines
offer little guidance for identifying patients whose clini-
cal situation is appropriate for admission to the hospital.
In addition, although some disease severity scores exist
for patients with stable COPD, no robust severity score
has been developed for patients experiencing an exacer-
bation [9].
Observational studies have not yet provided conclusive
information on steps that can be taken to improve the
process of care for patients experiencing exacerbations
of COPD, and randomized controlled trials are unlikely
to be conducted to shed light on this topic. One method
that can be used to address areas of clinical uncertainty
was designed by the Research and Development
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Los Angeles (UCLA). Called the RAND/UCLA Appro-
priateness Methodology (RAM), it can be used to deter-
mine best practices guidelines. It has previously been
used to improve clinical decision making in the emer-
gency department (ED) [10].
We used the RAM to create explicit criteria for hospi-
tal admission from the ED for patients with COPD
exacerbations [11,12]. To validate these criteria in real-
world clinical situations, we created the Investigacion en
Resultados y Servicios de Salud COPD Appropriateness
Study (IRYSS-CAS) group. The goals of this prospective
cohort study, which was conducted in 16 hospital EDs,
include validating the explicit criteria developed by the
RAM, evaluating the variability between hospitals in the
appropriateness of hospital admission of patients experi-
encing COPD exacerbations, and studying variability in
access to care and outcomes. We also developed a
robust severity scale for patients with COPD exacerba-
tions. In this report, we describe the protocol as well as
the methods needed for the collection of data and their
management.
Methods/Design
Development of appropriateness criteria
We used the RAND/UCLA Apropriateness Methodol-
ogy[10] to develop criteria for determining the appropri-
ateness of hospital admission for patients experiencing
exacerbations of COPD who attended an ED [11,12].
The methodology consists of the following steps:
First, an extensive literature review was conducted to
summarize existing knowledge about criteria for hospital
admission for patients attending an ED with exacerba-
tions of COPD.
Second, results from this review were used to develop
a comprehensive and detailed list of mutually exclusive
and clinically specific scenarios regarding hospitalization
for patients attending an ED with an exacerbation of
COPD. A total of 896 scenarios were created from com-
binations of the following variables: age, presence of dia-
betes mellitus, presence of cardiovascular disease,
expected adherence to treatment, response to prior
treatments, severity of baseline COPD, severity of
COPD exacerbation, number of hospital admissions in
the year preceding the exacerbation, and need for oxy-
gen therapy at home.
Third, we used a modified Delphi process[11,12] to
create appropriateness criteria. We assembled a panel of
7 pneumologists and 5 ED physicians who were nation-
ally recognized in their fields. Candidates’ names were
provided by their respective medical societies and mem-
bers of our research team. In the first round of the two-
round process, the panelists were mailed the literature
review and the 896 scenarios and asked to rate each
scenario for the appropriateness of hospital admission,
considering the average patient and physician in the
year 2007. Panelists were also given the definition of
“appropriate” established by the RAM: A procedure or
treatment is considered to be appropriate if the expected
health benefit exceeds the expected negative conse-
quences by a sufficiently wide margin that the procedure
is worth doing, exclusive of cost.
Panelists rated each scenario using a 9-point scale,
ranging from 1 point for an extremely inappropriate
admission to 9 points for an extremely appropriate
admission. Each panelist returned his or her ratings by
mail.
Members of the IRYSS-CAS team compiled and col-
lated the ratings. A scenario was defined as appropriate
if the panel’s median score was between 7 and 9 without
disagreement and inappropriate if the median score was
between 1 and 3 without disagreement. Scenarios were
defined as uncertain if the median score was between 4
and 6 or if the members of the panel disagreed. Dis-
agreement was defined as at least one-third of the pane-
lists rating a scenario from 1 to 3 and at least another
third rating it from 7 to 9; agreement was defined as
less than one third of the panelists rating an indication
outside a 3-point region (1 to 3, 4 to 6, or 7 to 9) con-
taining the median. If neither agreement nor disagree-
ment was found, the scenario was defined as uncertain.
The results of the first round were presented to the 12
panelists at a one-day meeting. During that meeting, the
panelists discussed variables and points of disagreement,
and rated the scenarios again. As before, members of
the IRYSS-CAS team compiled and collated the ratings
and created the final list of appropriate, uncertain, and
inappropriate scenarios.
For the appropriateness criteria, we created our own
explicit scale for measuring the severity of COPD
exacerbations because we did not find any in the litera-
ture. We based this scale on predictive factors for poor
prognosis for COPD, recommendations from guidelines,
and clinical knowledge of members of our research
team [11,12].
Development of the cohort study
A prospective cohort study was performed to validate
the explicit criteria developed by the RAM. Other goals
for the cohort study were to evaluate variability among
hospitals in the appropriateness of hospital admission of
patients experiencing COPD exacerbations and to study
variability in access to care and outcomes. Sixteen hos-
pitals belonging to the Spanish National Health Service
agreed to participate: Hospital Costa del Sol, Hospital
Valme, Hospital de Motril, Corporació Sanitaria Parc
Taulí, Hospital del Mar, Hospital Universitario de La
Princesa, Hospital Universitario Gregorio Marañón,
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Hospital Marqués de Valdecilla, Hospital Santa Marina,
Hospital San Eloy, Hospital Galdakao-Usansolo, Hospital
Txagorritxu, Complejo Hospitalario Donostia, and Hos-
pital Cruces.
Patients attending the EDs of any of the 16 hospitals
with an exacerbation of COPD were informed of the
goals of the study and invited to voluntarily participate
in it. All information was kept confidential. The Institu-
tional Review Boards of the participating hospitals
approved this project. Recruitment started in June 2008
and ended in September 2010.
Patients were candidates for the study if they pre-
sented to the ED of any of the participating hospitals
with symptoms consistent of an exacerbation of COPD.
Exacerbation was defined as an event in the natural
course of the disease characterized by a change in the
patient’s baseline dyspnea, cough, and/or sputum that
was beyond normal day-to-day variations, was acute in
onset, and may have warranted a change in regular
medication in a patient with underlying COPD [6]. Two
possible presentations were considered:
Existing COPD
Patients were considered to have been previously diag-
nosed with COPD if they had a FEV1/forced vital capacity
(FVC) quotient <70%, and a negative bronchodilation test
with FEV1 change <200 mL and under 15% of the base-
line value.
New COPD
Patients not previously diagnosed with COPD but in
whom the disease was suspected were also eligible for
inclusion in the study. This included smokers or former
smokers of more than 15 packs per year with dyspnea,
cough, or expectoration for more than three months per
year, and experiencing symptoms resembling a clinical
manifestation compatible with COPD exacerbation. The
diagnosis had to be confirmed by spirometry within 60
days after the index episode at a time when the patient
was stable, i.e., the absence of any increase in symptoms
or changes in background therapy [13]. If a diagnosis of
COPD was not confirmed, the patient was excluded
from the study [6].
Patients were excluded from the study if they had
COPD complicated by a comorbidity such as pneumo-
nia, pneumothorax, or pulmonary embolism; lung can-
cer; or left cardiac insufficiency. Other exclusion criteria
included a diagnosis of asthma, extensive bronchiectasis,
sequelae of tuberculosis, pleural thickening, or restrictive
diseases. Patients who did not wish to participate were
also excluded.
Data collected for the cohort study
A substantial amount of clinical and other data were
needed to meet the objectives of the IRYSS-CAS. Data
from several time points were needed: during the
patient’s evaluation in the ED; at the time the decision
was made to hospitalize the patient or discharge him or
her to home; in the medical ward (if needed); and dur-
ing post-hospitalization or post-discharge follow-up. It
must be noted that ED physicians were not asked to
gather any information other than what they would
usually collect for a patient experiencing an exacerbation
of COPD. Instead, trained data managers gathered data
from hospital and primary care medical records using a
manual of instructions that aimed to standardize data
collection.
Variables needed at each time point are listed in Table
1. Some of the information required a review of the
patient’s medical records. Patients admitted to the hos-
pital were interviewed at 1 and 7 days after admission.
Patients discharged from the ED to home were inter-
viewed by telephone at, around, 1 and 7 days after dis-
charge. All patients were interviewed by telephone 60
days after the index event.
In the ED
As is true for almost any encounter in the ED, substan-
tial information is gathered for a patient experiencing an
exacerbation of COPD. The main data collected were
those related to the patient’s respiratory function (Arter-
ial blood gases, respiratory rate, dyspnea), consciousness
level measured by the Glasgow Coma scale, [14] back-
ground, and presence of other pathologies as those
recorded in the Charlson Comorbidity Index [15]. Vari-
ables needed from the initial evaluation in the ED are
listed in Table 1.
At the time of decision making
Data collected at the ED decision time was related to
the patient’s respiratory status at that moment as well as
variables needed to create the appropriateness scenarios,
determine the severity of the exacerbation, and evaluate
other study criteria (Table 1).
In the hospital
For patients admitted to the hospital, we collected data
directly from the patient’s medical record and from a
direct interview with him or her from the first day after
admission until discharge (Table 1). Patients were inter-
viewed about their general health status (response to
question 1 of the Short Form 36 (SF-36) questionnaire
[16]), degree of dyspnea, based on the Medical Research
Council Dyspnea Index[17], physical activity level (based
on a scale employed previously in various studies[18])
and also completed the EuroQol-5D [19,20]. Patients
were also asked about social support and level of func-
tional dependency. This information was recorded in the
first 24 hours after arrival to the ED and at discharge.
Following discharge home from the ED
Among patients discharged home from the ED, tele-
phone interviews were conducted around 1 day, 7 days,
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Data needed at various time points
Evaluation in the ED
Arterial blood gases parameters including PO2, PCO2 and pH.
O2 saturation
Presence of diabetes mellitus
Presence of cardiovascular disease
Expected adherence to treatment
Response to previous treatments
Severity of baseline COPD
Number of hospital admissions in the year preceding the exacerbation
Need for oxygen therapy at home
Hemodynamic stability
Level of consciousness, measured by the Glasgow Coma Scale [14]
Presence of dyspnea at rest
Exercise tolerance in the ED
Respiratory rate
Presence of paradoxical breathing or use of accessory respiratory musculature
Sociodemographic information
Decision to admit or discharge home
Arterial blood gases parameters including PO2, PCO2 and pH.
O2 saturation
Hemodynamic stability
Level of consciousness, measured by the Glasgow Coma Scale[14]
Presence of dyspnea at rest
Respiratory rate
Presence of paradoxical breathing or use of accessory respiratory musculature
If admitted, in the hospital
Biological parameters such as arterial blood gases and blood glucose.
Respiratory rate
Presence of cardiac failure
Results of chest x-ray
Charlson Comorbidity Index[15]
Medications prescribed for the acute episode and subsequent admission, methods of administration, and number of days of intravenous drug
therapy.
In-hospital morbidity and mortality: the appearance of complications, including all signs, symptoms, syndromes or diseases, that appeared or
worsened during the hospital stay that were attributable to COPD or it treatment.
Death
Admission to an Intensive Care Unit (UCI) or to an Intermediate Respiratory Care Unit (IRCU); or need for Invasive Mechanical Ventilation (IMV)
or Non-Invasive Mechanical Ventilation (NIMV)
Length of stay
General health status, from response to question 1 of the Short Form 36 (SF-36) questionnaire[16], degree of dyspnea, based on the Medical
Research Council Dyspnea Index[17], and physical activity level (based on a scale employed previously in various studies at 1, and 7 days [18].
Quality of life, measured by the EuroQol-5D questionnaire at 1, and 7 days [19,20].
Follow-up on admitted patients (after hospital discharge and up to 60 days post-discharge)
General health status, from response to question 1 of the Short Form 36 (SF-36) questionnaire[16], degree of dyspnea, based on the Medical
Research Council Dyspnea Index[17], and physical activity level (based on a scale employed previously in various studies) [18].
Quality of life, measured by the EuroQol-5D questionnaire [19,20].
Readmission within 30 days of the index exacerbation for the same reason, or readmission for any reason within 60 days after the index
exacerbation
Complications, including all signs, symptoms, syndromes or diseases that appeared or worsened during the 60-day observation period
attributable to COPD or its treatment
Variables collected from medical records in all patients with known COPD
Baseline severity of COPD as measured by FEV1
Hospital admissions during the previous 12 months
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pnea, physical activity, and general health (see previous
description), the use of and response to medications,
need for supplemental oxygen, the need for visits to the
patient’s primary care physician, subsequent ED visits or
hospital readmissions, vital status, presence of other
symptoms, social support, and level of functional
dependency.
During follow-up
Data collected during follow-up included general health sta-
tus (SF-36 question), degree of dyspnea, physical activity
level, and quality of life, all as previously described. Read-
mission within 30 days of the index exacerbation for the
same reason, or readmission for any reason between 31 and
60 days after the index exacerbation was recorded, as were
complications, including all signs, symptoms, syndromes or
diseases, which appeared or worsened during the 60-day
observation period attributable to COPD or its treatment.
For all patients with known COPD, additional variables col-
lected from medical records include baseline severity of
COPD as measured by FEV1; hospital admissions during
the previous 12 months; baseline therapy (inhaled long-act-
ing beta agonist, long-acting anticholinergics, inhaled corti-
costeroid and/or supplemental oxygen), the presence of
associated diseases such as diabetes, hypertension, ischemic
heart disease and/or valve disease, cor pulmonale, peptic
ulcer disease, psychiatric disorders, rheumatic disease, his-
tory of stroke or deep vein thrombosis, and others needed
to determine the Charlson Comorbidity Index[15].
Definitions of outcome measures
The following outcomes were defined for the study dur-
ing admission, as well as at 7 days, and 60 days after the
index ED visit:
- Mortality.
- Very serious evolution of COPD, defined as any of
the following added to mortality: ICU admission, the
need for invasive mechanical ventilation, and/or cardiac
arrest.
- Serious evolution of COPD, defined as any of the
following added to very serious evolution: non-invasive
mechanical ventilation for more than 2 days when
mechanical ventilation was not needed before admission,
and/or admission to an intermediate respiratory care
unit for 2 or more days.
Several secondary outcomes were also defined:
- A variable called “complications” in which we noted
the presence of shock, cardiac arrhythmia, myocardial
ischemia, pulmonary embolism, pneumonia, pneu-
mothorax, or decompensated diabetes [21].
- A variable called “complicated evolution,” which
included patients having serious evolution of a COPD
exacerbation and/or complications described above.
-Medication use, which included medications needed
during admission, including intravenous corticosteroids,
diuretics, antibiotics, and oral medications.
-Length of hospital stay, defined as the difference
between the day of discharge and the day of admission.
Assumptions on missing information
In the IRYSS-CAS, participating ED physicians were not
expected or asked to gather extra information beyond
what they would ordinarily collect in their clinical prac-
tice, nor were they asked to use or complete special
study forms. Thus, information for some patients was
not recorded upon their arrival in the ED or at the time
the decision was made to hospitalize or discharge the
patient.
Table 1 Main data needed at various time points for the IRYSS-COPD Appropriateness Study (Continued)
Baseline therapy (inhaled long-acting beta agonist, long-acting anticholinergics, inhaled corticosteroid and/or supplemental oxygen)
Presence of associated diseases such as diabetes, hypertension, ischemic heart disease and/or valve disease, cor pulmonale, peptic ulcer disease,
psychiatric disorders, rheumatic disease, history of stroke or deep vein thrombosis, and others needed to determine the Charlson Comorbidity
Index
Social support and level of functional dependency
Following discharge home from the ED (1, 7, and 60 days post-discharge)
General health status, from response to question 1 of the Short Form 36 (SF-36) questionnaire[16], degree of dyspnea, based on the Medical
Research Council Dyspnea Index[17], and physical activity level (based on a scale employed previously in various studies at 1, 7, and at 60 days
[18].
Quality of life, measured by the EuroQol-5D questionnaire at 1, 7, and at 60 days [19,20].
Charlson Comorbidity Index[15]
Medication use
Response to medications
Need for supplemental oxygen
Visits to the patient’s primary care physician, subsequent ED visits or hospital readmissions
Death, complications, presence of other symptoms
Level of social support
Level of functional dependency
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interval were not random but were instead the result of
routine clinical practice. For example, if an ED physician
believes that a patient’s clinical situation is normal based
on arterial blood gases performed upon arrival in the
ED, there is no need to repeat arterial blood gases at the
time the decision is made to hospitalize or discharge the
patient. In such cases, pulse oximetry was generally per-
formed when the admission decision was made, or a
second arterial blood gases was performed in the ward.
Missing data regarding sociodemographic data, informa-
tion regarding the patient’s previous health situation, or
variables essential for completing the appropriateness
a l g o r i t h m( T a b l e2 )w e r ec o n s i d e r e dt ob er a n d o m .
Table 3 shows missing data for the clinical variables at
arrival to the ED and at the time of decision making for
admission or discharge.
To impute missing data when possible, we made the
following assumptions:
Assumptions to recover missing data from ED arrival
There were very few missing arterial blood gases data
from arrival in the ED, reducing assumptions to a mini-
mum. In most cases, when arterial blood gases data
were not available, O2 saturation data from pulse oxi-
metry was available. It was used to impute missing
arterial blood gases parameters as follows:
pH If a patient’s O2 saturation on arrival in the ED was
higher than 94% without the use of supplemental O2 ,
then we assumed the pH to be >=7.35.
PO2 If a patient’sO 2s a t u r a t i o no na r r i v a li nt h eE D
was higher than 94% without the use of supplemental
O2, PO2 was assumed to be >60 mmHg.
PCO2 No assumptions were made.
Respiratory frequency If the patient’s respiratory fre-
quency was described in the medical record as eupneic,
a respiratory frequency <20 breaths per minute was
assumed. For patients described as tachypneic, those
with paradoxical breathing, or those using accessory
musculature to breathe, a respiratory frequency >=20
was assumed.
Assumptions to recover missing data at the time of decision
making
W ea s s u m e dt h a tm o s to ft h em i s s i n gd a t af r o mt h e
time the decision was made to admit or discharge the
patient were not random but were generally due to phy-
sicians’ prior knowledge of data collected when the
patient arrived or their clinical evolution in the ED. For
example, 79% of the missing data on pH at the time of
decision making belonged to patients whose pH was
>=7.35 when they arrived in the ED, and only 21.5% of
patients whose pH was >=7.35 when they arrived in the
ED had a second arterial blood gases done. Patients
Table 2 Available sociodemographic and clinical data collected at arrival to the ED (n = 2877)
Number of patients n (%) % with missing data
Age* 2876 72.84 (9.51) 0.03
Clinical data previous to arrival at the ED
Heart disease - Yes 2856 617 (21.6) 0.7
Diabetes - Yes 2858 619 (21.66) 0.7
Charlson Comorbidity Index 2846 1.1
0 68 (2.39)
1 1116 (39.21)
>1 1662 (58.40)
Number of hospital admissions in the previous 12 months for COPD 2839 1.3
3 or more 360 (12.68)
Less than 3 2479 (87.32)
Basal FEV1% 2430 15.5
>= 50 809 (33.29)
<5 0 1621 (66.71)
Use of oxygen at home - Yes 2841 984 (34.64) 1.3
At arrival at the ED
Expected good adherence to treatment 2845 2681 (94.24) 1.1
Positive response to previous treatment - Yes 2849 2684 (94.21) 1.0
Edema - Yes 2712 516 (19.03) 5.8
Dyspnea upon arrival in the ED - Yes 2739 1834 (66.96) 4.8
Glasgow Coma Scale - altered 2874 77 (2.68) 0.1
*Represented as mean (std)
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arterial blood gases performed in the medical ward or
ICU. We recovered some missing information from
other available data by making the following assump-
tions, which in the analysis are planned to be done
sequentially as described below:
pH If the patient arrived in the ED with a pH >=7.35, and
the PO2 was >60 mmHg or the O2 saturation was
>=90%, and the O2 saturation was >94% when the deci-
sion was made to admit or discharge, and the patient was
discharged home, the pH at the decision time point was
assumed to be normal (>=7.35). If the patient arrived in
the ED with a pH >=7.35, and the PO2 was >60 mmHg
or the O2 saturation was >=90%, and the O2 saturation
was >94% when the decision was made to admit or dis-
charge the pH at the decision time point was assumed to
b en o r m a l( > = 7 . 3 5 ) .I ft h ep a t i e n ta r r i v e da tE Dw i t ha
PH>=7.35 and was admitted and the O2 saturation at the
arrival at the medical ward was >94 then we assumed the
PH at the decision making time to be >=7.35. Finally, for
patients who were admitted to the hospital, we used the
pH recorded at the arrival at the medical ward.
PO2 To impute missing PO2 at the time of decision
making, we first turned to O2 saturation data from
pulse oximetry recorded near the decision point. If O2
saturation was >94%, we assumed that the PO2 was >60
mmHg; if O2 saturation was <90%, the PO2 was
assumed to be >45 and <=60 mmHg. If the patient was
discharged home and the PO2 at arrival was >60 then
PO2 was assumed at the time of decision making to be
>60. If O2 saturation was not available near the decision
point and the patient was admitted, PO2 recorded at
the arrival at the medical ward was used as the value at
decision making. If PO2 was not recorded on admission
to the medical ward, but O2 saturation was available
and this was >94%, then we assumed that the PO2 was
>60 mmHg; for O2 saturation <90%, the PO2 was con-
sidered to be >45 mmHg and <=60 mmHg.
PCO2 If the patient was discharged home and the
PCO2 at arrival was <=45 then we assumed the PCO2
at decision making to be <=45. If the patient was
admitted, we used the PCO2 recorded at the arrival at
the medical ward when available.
Respiratory rate As was the case for ED arrival, if the
patient’s exact respiratory frequency was not recorded at
the decision point, a respiratory frequency of <20 breaths
per minute was assumed for patients described as eupneic
while a respiratory frequency >20 breaths per minute was
assumed for those described as tachypneic, those with
paradoxical breathing, or those using accessory muscula-
ture to breathe. If the patient was discharged home having
a respiratory frequency at arrival normal (<20) we
assumed a normal respiratory frequency to be at the deci-
sion time. If the patient was admitted and the respiratory
rate was available at the arrival at the medical ward, we
used this data as the value at the time of decision making.
Sample size estimation
Sample size estimations were made for some of the
main hypotheses. To detect a difference in the rate of
Table 3 Respiratory rate and arterial blood gases data available at arrival in the ED and the time a decision was made
to admit or discharge to home.
Without assumptions on missing data With assumptions on missing data
Arrival at ED Decision time Arrival at ED Decision time
N % missing n(%) N % missing n(%) N % missing n(%) N % missing n(%)
Respiratory Rate 2314 19.6 1536 46.6 2621 8.9 2200 23.5
<20 435 (18.80) 453 (29.49) 435 (16.60) 673 (30.59)
20-24 832 (35.96) 713 (46.42) 1139 (43.46) 1084 (49.27)
>24 1047 (45.25) 370 (24.09) 1047 (39.95) 443 (20.14)
pH 2494 13.3 747 74.0 2661 7.5 2410 16.2
>=7.35 2141 (85.85) 626 (83.80) 2308 (86.73) 2227 (92.41)
7.26-7.35 293 (11.75) 105 (14.06) 293 (11.01) 160 (6.64)
<7.26 60 (2.41) 16 (2.14) 60 (2.25) 23 (0.95)
PO2 2469 14.2 742 74.2 2642 8.17 2228 22.6
>60 1130 (45.77) 346 (46.63) 1303 (49.32) 1434 (64.36)
45 - 60 979 (39.65) 316 (42.59) 979 (37.06) 668 (29.98)
<=45 360 (14.58) 80 (10.78) 360 (13.63) 126 (5.66)
PCO2 2485 13.6 744 74.1 2485 13.6 1992 30.76
<=45 1365 (54.93) 313 (42.07) 1365 (54.93) 1106 (55.52)
45-55 592 (23.82) 204 (27.42) 592 (23.82) 544 (27.31)
55-65 288 (11.59) 118 (15.86) 288 (11.59) 184 (9.24)
>65 240 (9.66) 109 (14.65) 240 (9.66) 158 (7.93)
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best rates (<10%) and those with the worst rates
(>20%), 155 patients would be needed for a =0 . 0 5
and1-ß = 0.80. To develop predictive models for ser-
ious or complicated evolution of COPD, we needed at
least 10 instances of the dependent variable of interest
for each independent variable included in the multi-
v a r i a t el o g i s t i cr e g r e s s i o n[22]. With 10 independent
variables in the multivariate logistic regression model,
at least 100 such events of the dependent variable in
the sample from which we derived the prediction rule
would be needed to ensure that the logistic regression
model converges properly. Previous data from some of
our participating centers indicated that the number of
events of our dependent variable would be not more
than 20% of patients admitted with COPD exacerba-
tions. Therefore, to test this hypothesis, we needed to
r e c r u i ta tl e a s t1 , 0 0 0p a t i e n t st oh a v ee n o u g he v e n t si n
half the total sample which could constitute the deriva-
tion sample.
In summary, we planned to recruit at least 2,500
patients to answer the study’s hypotheses.
Statistical Analysis
We used means and standard deviations (SDs), frequen-
cies, and percentages to describe the sample. Sociode-
mographic, clinical data before attending the ED and at
t h eE Da sw e l la sm a i no u t c o m e sw e r ec o m p a r e d
between patients with missing data on arterial blood
gases variables (on the pH) at the ED decision making
time, versus those with complete data, by using the Chi-
square or Fisher’s exact tests for categorical variables
and the t-test or the Wilcoxon nonparametric test when
necessary.
To make clinical interpretation easier, we first categor-
ized variables based on commonly used clinical criteria
[6,13,23] and clinical expertise [13], and confirmed them
by the following statistical techniques[24].
- PCO2: <=45, 46 to 55, 56 to 65 and >65 mmHg
- pH: <=7.25, 7.26 to 7.34, and >=7.35
- PO2: >60, 46 to 60, and <=45 mmHg
- O2 saturation measured by pulse oximetry: >=94%
or <90%
- Respiratory rate: >15 to <20; 20 to 24; and >=25
breaths per minute
We then developed models of variables influencing
very serious evolution of COPD and serious evolution
using generalized additive models (GAM), searching for
cut-point estimation with smooth functions. When
necessary, a confidence interval was calculated for the
cut-point. The statistical techniques we used to explore
the relationship between covariate and outcome have
been covered in two steps:
1. We used GAM to graphically display the relation-
ship between each predictor and evolution of COPD,
the selected outcome of interest [25]. Each predictor
was included in a GAM in a flexible way, using P-
splines as smoothers [26]. These graphical displays
were used to select adequate cut-points of the con-
tinuous predictors in order to make them categorical
predictors. Cut-points were selected based on the
curvature and the slope of the smooth curve that
estimates the relationship of each predictor with the
outcome, considering the points where the smooth
curve crosses the x axis.
2. If the relationship between the predictor and the
outcome was linear, as is the case for respiratory fre-
quency, cut-points were selected based on the value
where the line crosses the x axis. This value was
selected as the zero risk point and a 95% prediction
confidence interval was built around it using a
regression logistic model. This yielded three cate-
gories: a middle one indicating no risk flanked by a
lower one indicating lower risk for the outcome and
an upper one indicating higher risk.
For variables where assumptions were made (arterial
blood gases parameters-pH, PCO2 and PO2- and
respiratory rate) at ED arrival or at ED decision time to
discharge home or admit the patient to the hospital, we
checked all the previously described assumptions (in the
same order as described) in the sample of patients who
had complete data in all points in time of the study.
All variables defined as outcomes of the study were
categorized as dichotomous: presence or absence.
Description and Characteristics of the IRYSS-COPD
Appropriateness Study (IRYSS-CAS) cohort
A total of 3,276 patients were recruited for the study. Of
these, 198 (6%) were excluded because their COPD was
complicated by other major pathologies at the time of
ED admission. Fifty-six patients of the patients who
entered the study as new diagnosis of COPD were
excluded when the diagnosis was not confirmed by
spirometry within 60 days of the index episode. Another
145 patients (4.4%) were lost during the follow-up
period.
Thus, the final study population included 2,877
patients who attended one of the 16 participating EDs
with an exacerbation of COPD. Of these, 1,747 patients
(60.7%) were admitted to the hospital and 1,130 (39.3%)
were discharged home from the ED (see Figure 1). At
follow up at 2 months after the ED index visit, 88.3% of
patients admitted to the hospital completed the inter-
view and had their medical record available, compared
with 86.7% of those discharged home.
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Page 8 of 16Sociodemographic and clinical variables from the arri-
val in the ED time were mostly complete (Table 2). Two
key variables in the clinical decision making process for
COPD– arterial blood gases and respiratory rate–were
available for more than 80% of the patients arrival at the
ED. After applying assumptions about missing informa-
tion, these data were missing for only 5% to 10% of
patients. Missing data were much more common at the
time the decision was made to admit or discharge (e.g.,
74% missing data for arterial blood gases). After apply-
ing assumptions, that was reduced to 16% to 31% (Table
3). For the main outcomes of our study, data were com-
plete, with less than 1% of missing data in most cases.
No assumptions were made for these missing variables
(Table 4). For cases where assumptions were made
(arterial blood gases and respiratory rate) at ED arrival
or at ED decision time to discharge home or admit the
patient to the hospital we checked all the previously
described assumptions (in the same order as described)
in the sample of patients who had complete data in all
points in time of the study. Results of this validation
process are included in Table 5. We, then, study the
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Figure 1 Exclusions and losses during all the study.
Table 4 Data available on outcome variables
Outcomes
Without Assumptions on Missing Data With Assumptions on Missing Data
N % miss N Outcome present
n(%)
Death 2852 0.87% 2877 60 (2.09)
Admission to Intensive Care Unit 2858 0.66% 2877 27 (0.94)
Invasive Mechanical Ventilation 2856 0.73% 2877 38 (1.32)
Admission to intermediate respiratory care unit 2858 0.66% 2877 74 (2.57)
Noninvasive mechanical ventilation 2840 1.29% 2877 100 (3.48)
Chronic oxygen therapy in the medical ward 2848 1.01% 2877 1512 (52.55)
Cardiac arrest 2789 3.06% 2877 20 (0.70)
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Page 9 of 16differences between those patients having arterial blood
gases information (pH) at the time the decision to admit
to the hospital or discharge home, with those patients
who did not have such information available (Table 6).
Patients with arterial blood gases information at the
decision time had poorer health status (on basal FEV1%,
previous admissions, use of oxygen at home; and dys-
pnea, Glasgow score and arterial blood gases at arrival)
and outcomes (admission to an intensive care unit
(ICU), admission to an intermediate respiratory care
unit (IRCU), need for invasive mechanical ventilation
(IMV) , non-invasive mechanical ventilation (NIMV) or
those with chronic oxygen therapy in the medical ward)
than those with missing data on those parameter.
We also descriptively explored the relationship
between the main arterial blood gases parameters
(PCO2, pH) and respiratory rate at the time of arrival in
t h eE Da n da tt h et i m et h ed e c i s i o nw a sm a d et oa d m i t
or discharge with the variable “serious evolution of
COPD” as well as the relationship of their respective
cut-off points (Figures 2, 3, 4) in order to confirm
visually if the commonly used cut-points for these para-
meters were associated with serious evolution of COPD
over short-term follow-up (for patients discharged home
from the ED, up to 7 days after discharge; for patients
admitted to the hospital, until discharge from the hospi-
tal in admitted patients). As can be seen in the figures,
the data confirm the use of these commonly used cut-
points to established normality or increased risk of ser-
ious evolution of COPD.
Discussion
Little evidence-based guidance is available to ED physi-
cians when deciding whether to hospitalize a patient
experiencing an exacerbation of COPD or to discharge
him or her to home from the ED. In the absence of clin-
ical trial data, other methods are needed to establish evi-
dence-based processes of care for this common clinical
scenario. We approached this problem by creating a set
of appropriateness criteria for hospitalization using the
RAND/UCLA Appropriateness Methodology and then
applying these criteria in a prospective study conducted
in the EDs of 16 hospitals.
Data collection in the prospective study posed some
unique problems. In order to complete the appropriate-
ness criteria algorithm, data were needed from the ED
at two points in time–patient arrival in the ED and
when the decision was made to admit the patient to the
hospital or to discharge him or her to home from the
ED. This presented a challenge because of missing data
at one or both of these time points. For example, arter-
ial blood gases information was missing for 74% of
patients at the time the decision was made to admit or
discharge home. This is largely due to physician knowl-
edge of data collected when the patient arrived in the
ED–if a patient’s arterial blood gases were normal upon
arrival in the ED, there is generally no need to carry out
a second arterial blood gases at the time the decision is
made to hospitalize or discharge the patient. We made
several pre-defined assumptions that allowed us to reli-
ably impute missing data in many instances.
Table 5 Validation of missing data assumptions on complete data patients
Validation of the
assumptions made at
arrival
N and % of missing data
recovered with each
assumption
Validation of the assumptions made
at the decision time
N and % of missing data
recovered with each
assumption
Respiratory
Rate
1. 91% 1. 307 (54.5%) 1. 88%
2. 90%
3. 64% (when FR<20), 70% (when FR
[20-24]) and 58% (FR>24)
1. 263 (19.6%)
2. 134 (10%)
3. 267 (19.9%)
pH 1. 90% 1. 167 (43.6%) 1. 97%
2. 98%
3. 98%
4. 91% (pH>=7.35), 63% (pH [7.26-7.35])
and 50% (pH<7.26)
1. 937 (44%)
2. 146 (6.9%)
3. 181 (8.5%)
4. 399 (18.7%)
PO2 1. 95% 1. 173 (42.4%) 1. 90% for O2 saturation >94%; 70% for
O2 saturation <90%
2. 91%
3. 77% (PO2>60), 82% (PO2 (45-60]) and
63% (PO2 <=45)
4. 63% for O2 saturation >94%; 64% for
O2 saturation <90%
1. 637 (29.8%)
2. 342 (16%)
3. 386 (18.1%)
4. 121 (5.7%)
PCO2 No assumptions were
made
1. 90% if PCO2 at arrival normal
2. 86% (PCO2 <=45), 73% (PCO2 (45-55])
, 75% (PCO2 (55-65]) and 80%
(PCO2>65)
1. 714 (33.5%)
2. 534 (25%)
Numbers in cells indicated, first, the order of the assumption, as included in the manuscript text, and, then, the percentage of patients with complete data that
fulfill that assumption.
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Page 10 of 16To the best of our knowledge, no prior studies have
focused on the development or validation of admission
criteria for patients experiencing exacerbations of
COPD. Although Roche et al. developed predictive mod-
els to create severity scores for such patients,[9] their
score does not include arterial blood gases and other
relevant data from the ED, which limits their results.
The IRYSS-CAS has several strengths. One is the use
of the systematic, validated RAND/UCLA Appropriate-
ness Methodology for creating appropriateness criteria
Table 6 Comparison of sociodemographic, clinical and outcome parameters among patients with arterial blood gases
data available at decision making versus those with missing data at that time.
Patients without missing data
N = 747
Patients with missing data
N = 2130
p value
Age* 72.54 (9.50) 72.94 (9.51) 0.3311
Clinical data previous to arrival at the ED
Charlson Index 0.5522
<=1 301 (40.68) 883 (41.93)
>1 439 (59.32) 1223 (58.07)
Number of hospital admissions in the previous 12 months for COPD <.0001
3 or more 128 (17.34) 232 (11.04)
Less than 3 610 (82.66) 1869 (88.96)
Basal FEV1% <.0001
>= 50 169 (25.61) 640 (36.16)
< 50 491 (74.39) 1130 (63.84)
Use of oxygen at home - Yes 336 (45.41) 648 (30.84) <.0001
At arrival at the ED
Glasgow Coma Scale - altered 34 (4.55) 43 (2.02) 0.0002
Edema - Yes 153 (21.37) 363 (18.19) 0.0627
Dyspnea upon arrival in the ED - Yes 546 (76.36) 1288 (63.64) <.0001
PH at arrival <.0001
>=7.35 462 (69.79) 1679 (91.65)
7.26-7.35 156 (23.56) 137 (7.48)
<7.26 44 (6.65) 16 (0.87)
PO2 at arrival <.0001
>60 229 (35.12) 901 (49.59)
45 - 60 273 (41.87) 706 (38.86)
<=45 150 (23.01) 210 (11.56)
Respiratory rate at arrival <.0001
<20 79 (12.38) 356 (21.24)
20-24 209 (32.76) 623 (37.17)
>24 350 (54.86) 697 (41.59)
PCO2 at arrival <.0001
<=45 243 (36.82) 1122 (61.48)
46-55 165 (25.00) 427 (23.40)
56-65 117 (17.73) 171 (9.37)
>65 135 (20.45) 105 (5.75)
Outcome parameters
Death 18 (2.41) 42 (1.97) 0.4712
Admission to Intensive Care Unit 14 (1.87) 13 (0.61) 0.0021
Invasive Mechanical Ventilation 16 (2.14) 22 (1.03) 0.0223
Admission to Intermediate respiratory care unit 50 (6.69) 24 (1.13) <.0001
Noninvasive mechanical ventilation 57 (7.63) 43 (2.02) <.0001
Chronic oxygen therapy in the medical ward 476 (63.72) 1036 (48.64) <.0001
Cardiac arrest 6 (0.80) 14 (0.66) 0.6796
*Mean (Std)
Patients were included in the patients with missing data at decision making time group if they did not have the pH data available at that time. If they had it,
they were included in the group with no missing data at that time.
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Page 11 of 16for the hospitalization of patients experiencing COPD
exacerbations. Another strength is our effort to validate
these criteria in a large prospective cohort of patients
recruited from 16 different EDs.
Limitations of the study must also be noted. As in any
prospective cohort study, patients lost to follow-up is an
issue. Among patients admitted to the hospital, 11.7%
did not complete the 60-day interview, compared with
Figure 2 Relationship of PCO2 at ED arrival and the decision to admit or discharge with serious evolution of COPD in the short
follow-up.
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Page 12 of 1613.3% of those discharged home. This is similar to rates
seen in other large multicenter clinical studies [27].
Missing data for some key variables is another limita-
tion. In a study like the IRYSS-CAS, clinical practice
prevails over research requirements. Thus, we had to
work with the information routinely collected in the ED
for patients experiencing COPD exacerbations. We cre-
ated a set of predefined assumptions that allowed us to
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Figure 3 Relationship of pH at ED arrival and the decision to admit or discharge with serious evolution of COPD in the short follow-
up.
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Page 13 of 16impute some missing data. These assumptions always
considered the criteria used in clinical practice and took
a conservative approach. It must also be noted that the
patient population was almost entirely comprised of
men (97%). Similar gender distributions have been
observed in other studies performed in our country [28],
which probably reflects our smoking patterns in the
mid-20
th century. Although we do not consider this to
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Figure 4 Relationship of respiratory rate ED arrival and the decision to admit or discharge with serious evolution of COPD in the
short follow-up.
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Page 14 of 16be a serious limitation, it could affect the generalizability
of the results.
In summary, the IRYSS-CAS will better delineate the
requirements for hospital admission or discharge home
for patients experiencing exacerbations of COPD and
also provide a better understanding of the determinants
of outcomes of COPD exacerbations. From a health ser-
vice research perspective, the study will also help evalu-
ate differences in appropriateness of hospitalization for
COPD exacerbation between hospitals, as well as differ-
ences in outcomes between hospitals and their relation-
ships with other parameters, such as sociodemographic
or clinical variables.
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